Cargando…
Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
The use of small molecules became one key cornerstone of targeted anti-cancer therapy. Among them, tyrosine kinase inhibitors (TKIs) are especially important, as they were the first molecules to proof the concept of targeted anti-cancer treatment. Since 2001, TKIs can be successfully used to treat c...
Autores principales: | Kaehler, Meike, Cascorbi, Ingolf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273252/ https://www.ncbi.nlm.nih.gov/pubmed/34262462 http://dx.doi.org/10.3389/fphar.2021.696960 |
Ejemplares similares
-
Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models
por: Kaehler, Meike, et al.
Publicado: (2023) -
Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009) -
Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells
por: Kaehler, Meike, et al.
Publicado: (2022) -
Pharmacogenomics in practice: a review and implementation guide
por: Kabbani, Danya, et al.
Publicado: (2023) -
Germline variants in cancer therapy
por: Kaehler, Meike, et al.
Publicado: (2019)